Mary Jo M. Dales

News

Bendamustine-Rituximab Doubles Progression-Free Survival in Indolent Lymphomas

Author:: Mary Jo M. Dales

Publish date: June 3, 2012

News

NSCLC: FDA Approves Crizotinib, Companion Diagnostic Test

Author:: Mary Jo M. Dales

Publish date: August 26, 2011

News

Many Cancer Patients Face Crippling Costs

Author:: Mary Jo M. Dales

Publish date: July 6, 2011

Major Finding: First-time bankruptcy filings averaged 0.5% of patients at 1 year after cancer diagnosis and 1.9% at 5 years after diagnosis. Avera...

News

Many Cancer Patients Face Crippling Costs

Author:: Mary Jo M. Dales

Publish date: July 6, 2011

Major Finding: First-time bankruptcy filings averaged 0.5% of patients at 1 year after cancer diagnosis and 1.9% at 5 years after diagnosis. Avera...

News

Many Cancer Patients Face Crippling Costs

Author:: Mary Jo M. Dales

Publish date: July 6, 2011

Major Finding: First-time bankruptcy filings averaged 0.5% of patients at 1 year after cancer diagnosis and 1.9% at 5 years after diagnosis. Avera...

News

Rich Patients With Poor Prognosis Cancers Get More Treatment

Author:: Mary Jo M. Dales

Publish date: June 20, 2011

Major Finding: For the lowest socioeconomic group of patients with lung cancer, radiation therapy was given to 44%, surgery to 13%, and chemothera...

News

Rich Patients With Poor Prognosis Cancers Get More Treatment

Author:: Mary Jo M. Dales

Publish date: June 20, 2011

Major Finding: For the lowest socioeconomic group of patients with lung cancer, radiation therapy was given to 44%, surgery to 13%, and chemothera...

News

Rich Patients With Poor Prognosis Cancers Get More Treatment

Author:: Mary Jo M. Dales

Publish date: June 20, 2011

Major Finding: For the lowest socioeconomic group of patients with lung cancer, radiation therapy was given to 44%, surgery to 13%, and chemothera...

News

Ipilimumab Added to Dacarbazine Prolongs Survival for Metastatic Melanoma

Author:: Mary Jo M. Dales

Publish date: June 5, 2011

Major Finding: Nearly 21% of 250 metastatic melanoma patients who underwent first-line treatment with ipilimumab (Yervoy, Bristol-Myers Squibb) in...

Video

ASCO: Ipilimumab Plus Dacarbazine Prolongs Metastatic Melanoma Survival

Author:: Mary Jo M. Dales

Publish date: June 5, 2011

Major Finding: Nearly 21% of 250 metastatic melanoma patients who underwent first-line treatment with ipilimumab (Yervoy, Bristol-Myers Squibb) in...

News

Ipilimumab Added to Dacarbazine Prolongs Survival for Metastatic Melanoma

Author:: Mary Jo M. Dales

Publish date: June 5, 2011

Major Finding: Nearly 21% of 250 metastatic melanoma patients who underwent first-line treatment with ipilimumab (Yervoy, Bristol-Myers Squibb) in...

News

Screening Does Not Reduce Ovarian Cancer Mortality

Author:: Mary Jo M. Dales

Publish date: June 4, 2011

Major Finding: Among women who underwent screening with the CA 125 blood test and transvaginal ultrasound, 118 died of ovarian cancer, whereas 100...

News

Screening Does Not Reduce Ovarian Cancer Mortality

Author:: Mary Jo M. Dales

Publish date: June 4, 2011

Major Finding: Among women who underwent screening with the CA 125 blood test and transvaginal ultrasound, 118 died of ovarian cancer, whereas 100...

News

Menactra Approved for Children 9 Months and Older

Author:: Mary Jo M. Dales

Publish date: April 22, 2011

News

There's a New Look for Internal Medicine News

Author:: Mary Jo M. Dales

Publish date: January 1, 2010